Scilex (SCLX) News Today → 41 banks launch ‘crypto dollar’ (From Stansberry Research) (Ad) Free SCLX Stock Alerts $0.90 +0.03 (+3.45%) (As of 05/17/2024 08:54 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 20 at 6:24 AM | americanbankingnews.comScilex Holding (NASDAQ:SCLX) Insider Acquires $69,771.24 in StockMay 18 at 10:41 AM | insidertrades.comScilex Holding (NASDAQ:SCLX) Director Purchases $51,750.00 in StockMay 18 at 1:44 AM | americanbankingnews.comAnalysts Offer Predictions for Scilex Holding's Q2 2024 Earnings (NASDAQ:SCLX)May 17 at 7:57 PM | marketbeat.comScilex Holding (NASDAQ:SCLX) Director Jay Chun Purchases 57,500 SharesScilex Holding (NASDAQ:SCLX - Get Free Report) Director Jay Chun bought 57,500 shares of the business's stock in a transaction on Friday, May 17th. The stock was purchased at an average cost of $0.90 per share, for a total transaction of $51,750.00. Following the transaction, the director now owns 102,500 shares of the company's stock, valued at $92,250. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.May 17 at 7:09 AM | marketbeat.comQ2 2024 EPS Estimates for Scilex Holding (NASDAQ:SCLX) Decreased by AnalystScilex Holding (NASDAQ:SCLX - Free Report) - Research analysts at Zacks Small Cap reduced their Q2 2024 earnings per share (EPS) estimates for Scilex in a report issued on Tuesday, May 14th. Zacks Small Cap analyst B. Sorensen now anticipates that the company will post earnings of ($0.26) per shaMay 14, 2024 | msn.comSCLX Grows Revenue and Expands PortfolioMay 14, 2024 | msn.comScilex wins court approval for Takeda settlementMay 14, 2024 | marketbeat.comScilex (NASDAQ:SCLX) Stock Price Up 0.2%Scilex (NASDAQ:SCLX) Shares Up 0.2%May 14, 2024 | msn.comSCLX Stock Earnings: Scilex Holding Misses EPS, Misses Revenue for Q1 2024May 14, 2024 | finance.yahoo.comScilex Holding Company Announces Final Court Approval of a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s intent to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba®May 13, 2024 | globenewswire.comScilex Holding Company Provides Information to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common StockMay 12, 2024 | americanbankingnews.comScilex (NASDAQ:SCLX) Shares Down 5.9% May 10, 2024 | marketbeat.comScilex (NASDAQ:SCLX) Trading Down 5.9%Scilex (NASDAQ:SCLX) Shares Down 5.9%May 9, 2024 | marketbeat.comScilex (NASDAQ:SCLX) Stock Price Down 0.9%Scilex (NASDAQ:SCLX) Trading Down 0.9%May 3, 2024 | markets.businessinsider.comMaintaining Buy Rating on Scilex: Strategic and Financial Optimism Despite ChallengesApril 26, 2024 | investing.comScilex secures $15 million in registered direct offeringApril 25, 2024 | globenewswire.comScilex Holding Company Announces Closing of $15 Million Registered Direct OfferingApril 24, 2024 | globenewswire.comScilex Holding Company Announces $15 Million Registered Direct OfferingApril 16, 2024 | msn.comScilex to reduce R&D expenses in 2024, comments on actions post Change Healthcare cyberattackApril 16, 2024 | globenewswire.comScilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative ExpensesApril 9, 2024 | globenewswire.comScilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing PoolMarch 27, 2024 | globenewswire.comScilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a DividendMarch 21, 2024 | globenewswire.comScilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured PatientsMarch 20, 2024 | globenewswire.comScilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba® Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is NeededMarch 20, 2024 | globenewswire.comScilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex's Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba®March 19, 2024 | msn.comScilex Holding repays the remaining balance of convertible debenturesMarch 19, 2024 | globenewswire.comScilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and InnovationMarch 18, 2024 | globenewswire.comScilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in CanadaMarch 16, 2024 | finance.yahoo.comSCLX Apr 2024 2.000 putMarch 16, 2024 | finance.yahoo.comSCLX Apr 2024 1.000 putMarch 15, 2024 | globenewswire.comScilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc.March 15, 2024 | markets.businessinsider.comScilex Pharma Enters Definitive Mutual Release And Settlement Agreement With VirpaxMarch 15, 2024 | finance.yahoo.comScilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Such Release and SettlementMarch 15, 2024 | globenewswire.comScilex Holding Company's Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Such Release and SettlementMarch 15, 2024 | marketbeat.comZacks Small Cap Analysts Increase Earnings Estimates for Scilex Holding (NASDAQ:SCLX)Scilex Holding (NASDAQ:SCLX - Free Report) - Analysts at Zacks Small Cap raised their Q1 2024 earnings per share (EPS) estimates for shares of Scilex in a research report issued on Tuesday, March 12th. Zacks Small Cap analyst B. Sorensen now forecasts that the company will earn ($0.10) per shareMarch 14, 2024 | finance.yahoo.comScilex Holding Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 12, 2024 | finance.yahoo.comSCLX Grows Revenue and Boosts MarketingMarch 9, 2024 | finance.yahoo.comScilex Holding Company (NASDAQ:SCLX) most popular amongst private companies who own 57% of the shares, institutions hold 25%March 7, 2024 | marketbeat.comQ2 2024 EPS Estimates for Scilex Holding Boosted by Analyst (NASDAQ:SCLX)Scilex Holding (NASDAQ:SCLX - Free Report) - Research analysts at Zacks Small Cap upped their Q2 2024 earnings per share estimates for Scilex in a research note issued on Tuesday, March 5th. Zacks Small Cap analyst B. Sorensen now anticipates that the company will earn ($0.14) per share for the qMarch 6, 2024 | msn.comSCLX Continues to Make StridesMarch 5, 2024 | globenewswire.comScilex Holding Company Announces Closing of $10 Million Bought Deal OfferingMarch 5, 2024 | globenewswire.comScilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba®, its First and Only Liquid Oral Version of the Anti-Gout Medicine Colchicine Indicated for the Prophylaxis of Painful Gout Flares in Adults; Expected Plans to Launch in the First Half of 2024March 4, 2024 | globenewswire.comScilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information UpdatesMarch 2, 2024 | globenewswire.comScilex Holding Company Announces that the Official Committee of Unsecured Creditors of Sorrento Therapeutics, Inc., has Filed a Motion with the U.S. Bankruptcy Court to Extend the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend from March 31, 2024 to September 30, 2024March 1, 2024 | marketwatch.comScilex Holding Shares Drop 31% After $10M Offering PricesFebruary 29, 2024 | msn.comScilex to raise $10M via bough deal offeringFebruary 29, 2024 | globenewswire.comScilex Holding Company Announces $10 Million Bought Deal OfferingFebruary 28, 2024 | globenewswire.comScilex Holding Company Announces Major Initiative with a Leading National Pharmacy Chain to Stock GLOPERBA® in Most of Their Stores Throughout the U.S.February 27, 2024 | msn.comScilex and Sorrento settle with Virpax and its founder Anthony MackFebruary 27, 2024 | globenewswire.comScilex Holding Company Announces Acceptance of Abstract for Poster and Oral Presentation at the Annual Meeting of the American Academy of Pain Medicine (AAPM) Get Scilex News Delivered to You Automatically Sign up to receive the latest news and ratings for SCLX and its competitors with MarketBeat's FREE daily newsletter. Email Address Shocking: One AI startup's revenue could surge 4,735% (Ad)Shocking: One AI Startup's Revenue Could Surge 4,735% While Nvidia gets all the attention, one small AI startup is quietly positioning itself to be the biggest winner. Click here to discover the AI chip company SCLX Media Mentions By Week SCLX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SCLX News Sentiment▼0.400.42▲Average Medical News Sentiment SCLX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SCLX Articles This Week▼172▲SCLX Articles Average Week Get Scilex News Delivered to You Automatically Sign up to receive the latest news and ratings for SCLX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: OMGA News MOLN News VIGL News LIFE News BCAB News SGMO News CRDL News BLUE News DBVT News VXRT News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SCLX) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport SocietyUrgent Nvidia WarningAltimetryElon’s New Device is About to Shock the WorldInvestorPlace"The Biggest Drug Ever" Is ComingBehind the MarketsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scilex Holding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
